Innovations has committed over £527 million to translational projects across 185 institutions and in excess of 100 companies. On aggregate, over £1.06 billion has been generated in third-party finance for these projects.
The types of project we support span computational chemistry to drug discovery, vaccine formulation and human proof-of-principle studies for medical devices, diagnostics and candidate pharmaceutical compositions. Therapeutic areas include cancer, the central nervous system, infectious diseases, inflammation, metabolism, tissue and wound healing.
The projects we have funded can be split broadly into the following areas:
- enabling technology
- regenerative medicine
- therapeutics (including Seeding Drug Discovery)
- medical devices
Health Innovation Challenge Fund
The Health Innovation Challenge Fund (HICF) is a parallel funding partnership between the Wellcome Trust and the Department of Health. The funders are collaborating to stimulate the creation of innovative healthcare products, technologies and interventions, and facilitate their development for the benefit of patients in the NHS and beyond. The HICF has a succession of thematic calls for proposals, each selected to focus on unmet needs in healthcare relevant to the NHS. The HICF offers translational funding to progress innovative approaches to healthcare from the proof-of-concept stage to early clinical studies in man. Details of the funded projects can be found here.